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SUMMARY  30 
Setting 31 
Incidence rates of tuberculosis in South Africa are amongst the highest in the world, and 32 
drug-resistance is a major concern. Understanding geographic variation in disease may 33 
guide targeted interventions.  34 
Objective 35 
We aimed to characterise the spatial distribution of drug-resistant tuberculosis (DRTB) in a 36 
rural area of KwaZulu-Natal, South Africa, and test for clustering. 37 
Design 38 
This was a cross-sectional analysis of DRTB patients managed at a rural district hospital 39 
from 2011-2015. We mapped all patients in hospital data to local areas; and linked to a 40 
population-based demographic surveillance system to map patients to individual 41 
homesteads. We used kernel density estimation to visualise the distribution of disease and 42 
tested for clustering using spatial scan statistics. 43 
Results 44 
There were 489 patients with DRTB in the sub-district; 111 lived in the smaller demographic 45 
surveillance area. Spatial clustering analysis identified a high-risk cluster (relative risk of 46 
DRTB within cluster compared to outside: 3.0, p<0.001) in the south-east, a region 47 
characterised by high population density and high HIV prevalence.   48 
Conclusion 49 
We have demonstrated evidence of a geographic high risk cluster of DRTB. This suggests 50 
that targeting interventions to spatial areas of highest risk, where transmission may be 51 
ongoing, could be effective.  52 
  53 
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INTRODUCTION 54 
Incidence rates of tuberculosis (TB) in South Africa are amongst the highest in the world.1 In 55 
2015 there were an estimated 454,000 new diagnoses, a rate of 834 per 100,000 56 
population, and it is the leading natural cause of death in the country.1, 2 Rates of TB are 57 
particularly high in the province of KwaZulu-Natal, largely driven by the high prevalence of 58 
human immunodeficiency virus (HIV) and complicated by TB drug resistance.3, 4 59 
Understanding the spatial distribution of disease is important for effective control. Spatial 60 
analyses can be used to identify the worst affected areas, generate hypotheses about 61 
transmission, and guide interventions.5 Tests of spatial clustering can be used to identify 62 
groups of patients that occur closer together in space than would be expected by chance. 63 
These analyses have been used to identify areas of likely TB transmission.6-14 Visualisation 64 
of spatial data on maps also provides a powerful means of communicating information about 65 
the disease to policy makers and the public.  66 
The Africa Health Research Institute (AHRI) in the Hlabisa sub-district of KwaZulu-Natal, 67 
South Africa, maintains a large health and demographic surveillance system. This includes 68 
individual residential locations mapped to an accuracy of less than two metres, and routine 69 
linkage to public sector records.15, 16 The aim of this study was to characterise the spatial 70 
distribution of drug-resistant TB (DRTB) in the sub-district, test for spatial clustering, and 71 
discuss implications for prevention and care.  72 
 73 
STUDY POPULATION AND METHODS 74 
Study area 75 
Hlabisa health sub-district is an area of approximately 1,450km2 and 247,350 residents in 76 
uMkhanyakude district, northern KwaZulu-Natal, South Africa (Figure 1A). It is characterised 77 
by high prevalence of HIV with high rates of associated TB (577 recorded TB cases per 78 
100,000 population in uMkhanyakude in 2015; 64.3% HIV positive).3, 17 The AHRI 79 
demographic surveillance area is located within the Hlabisa sub-district (Figure 1B). This a 80 
region of 435km2, with approximately 11,000 homesteads and 60,000 residents, in which 81 
AHRI has undertaken population-based demographic surveillance since 2000.15  82 
Data sources and identification of DRTB patients 83 
This was a cross-sectional analysis of patients diagnosed with DRTB between 2011 and 84 
2015 who were resident in the Hlabisa health sub-district. Since 2011, all patients with DRTB 85 
aged 12 years and older were admitted to the TB ward at Hlabisa hospital for at least the 86 
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first month of treatment. Since July 2013, individuals in the sub-district with DRTB have been 87 
identified through Xpert MTB/RIF testing at one of 17 primary health care clinics. Prior to 88 
that, most patients were identified through culture-based methods, apart from a small 89 
number of patients diagnosed using Xpert MTB/RIF tests at a clinical trial site.18  90 
We identified patients with DRTB using ICD-10 discharge codes in the Hlabisa hospital 91 
information system. We defined DRTB based on South African coding standards, 92 
incorporating codes for rifampicin mono-resistant, multidrug-resistant (MDR) and extensively 93 
drug-resistant (XDR) TB.19 We calculated the proportion of patients in the hospital 94 
admissions data who had DRTB, and described characteristics of patients. Data from the 95 
hospital information system are routinely linked to the AHRI demographic surveillance data 96 
using the South African identification number or through a standard probabilistic matching 97 
algorithm.15 We used linked data to identify individual homestead locations. 98 
The research was approved by the Biomedical Research Ethics Committee of the University 99 
of KwaZulu-Natal (ref. BE290/16), the Ethics Committee of the London School of Hygiene 100 
and Tropical Medicine (ref. 11814), and the Health Research Committee of the KwaZulu-101 
Natal Department of Health (ref. 378/16). These committees waived the requirement for 102 
individual informed consent to use the hospital admissions data, as the data were routinely 103 
collected from hospital records and there was no direct interaction with individual patients. 104 
Spatial analysis 105 
We conducted two spatial analyses which derived patient geographic locations using 106 
different methods: a local area analysis which covered the entire Hlabisa sub-district; and a 107 
micro-geographic analysis using the precise locations of patient homesteads within the 108 
smaller AHRI demographic surveillance area.  109 
In the local area analysis, we compared the spatial distribution of DRTB patients with all 110 
other hospital admissions. Local areas are informal regions used by local populations to 111 
describe the sub-district, and have been mapped by AHRI (315 local areas in the Hlabisa 112 
sub-district in total, Figure 1B). We extracted patient-reported local areas of residence from a 113 
free text field in the hospital data, and matched them to mapped names of local areas. 114 
In the micro-geographic analysis, we compared point residential locations for patients with 115 
DRTB to the spatial distribution of the general population. We used residential locations from 116 
the AHRI demographic surveillance data. For DRTB patients, we identified the exact 117 
homestead of residence which was recorded in the surveillance system closest in time to the 118 
patient’s date of admission to Hlabisa hospital. The distribution of the general population was 119 
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derived by calculating total person years of residence in each homestead over the study 120 
period.  121 
We tested for spatial clustering of DRTB in both the local area and micro-geographic 122 
analyses. We used spatial scan statistics, implemented in the SaTScan software,20 to test 123 
the hypothesis that DRTB patients were closer together in space than the underlying 124 
population distribution. Scan statistics are used to compare the observed number of cases 125 
within spatial windows of various sizes with those that would be expected, in this case, under 126 
a random Poisson distribution. A likelihood ratio is calculated for each window which 127 
compares the observed and expected numbers of cases inside and outside the window. 128 
Monte Carlo simulations are then used to generate random distributions of cases under the 129 
Poisson distribution, which are compared to the observed data to calculate a p-value. We set 130 
the maximum cluster size to 3 km, because spatial dependencies have previously been 131 
reported for HIV within this distance in this study area.21  132 
We also plotted the locations of clusters on a smoothed map of the relative proportion of 133 
DRTB patients compared to the underlying distribution in continuous geographical space. 134 
These maps were produced using kernel density estimation with a standard Gaussian kernel 135 
of 3km radius.  136 
Analyses were performed using R v 3.2.3, using the packages spatstat and rsatscan.22, 23 137 
 138 
RESULTS 139 
Between 2011 and 2015, there were 19,408 individuals admitted to Hlabisa hospital who 140 
could be allocated to a local area in the Hlabisa sub-district. Of these, 489 (2.5%) had an 141 
ICD-10 hospital discharge code indicating DRTB, among whom the majority (478, 98%) had 142 
MDR disease.  143 
Characteristics of patients with DRTB are shown in Table 1. Approximately half (250, 51%) 144 
the patients were female, and the modal age group was 25-34 years. There were 340 (70%) 145 
HIV positive DRTB patients, among whom 202 (60%) were on antiretroviral therapy at the 146 
time of admission. One in six (78, 16%) DRTB patients died prior to discharge, and five 147 
absconded from hospital.  148 
Local area analysis of DRTB in the Hlabisa sub-district 149 
We used the distribution of all 19,408 patients admitted to Hlabisa hospital across the local 150 
areas in the sub-district as a denominator for analyses of spatial clustering amongst the 489 151 
DRTB patients.  152 
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There was one high relative risk cluster, located in the south-east of the sub-district 153 
(p<0.001). This cluster had a radius of 1.9 km, comprised four local areas with a total of 79 154 
DRTB patients compared to 29 that would be expected by chance, and had a relative risk of 155 
3.0. There was some evidence of a low relative risk cluster in the west of the sub-district, 156 
close to the hospital (p=0.08). This cluster had a radius of 2.1 km; comprised four local areas 157 
with six patients compared to 19 expected, and a relative risk of 0.3. Locations of these two 158 
clusters, overlaid on a smoothed map of the relative proportion of DRTB patients compared 159 
to all hospital admissions are displayed in Figure 2. 160 
Micro-geographic analysis of DRTB in the AHRI demographic surveillance area 161 
There were 144 DRTB patients whose hospital data could be linked to the AHRI population 162 
surveillance data. Of these, 111 had a recorded homestead location during the study period 163 
and were included in the analysis (94 patients had a residential location recorded in the 164 
same year as their admission date; 16 of the remaining patients had a residence recorded 165 
before their admission date, and one had a residence location recorded the year after their 166 
admission date). The remaining 33 patients were excluded from this analysis because they 167 
did not have a homestead of residence recorded during the period of this study (2011-2015). 168 
The 111 patients with DRTB resided at 106 unique homestead locations; 10 patients shared 169 
homesteads with another patient. The most likely high relative risk cluster (p=0.057) had a 170 
radius of 2.8 km. The cluster comprised 55 patients compared to 31 that would be expected 171 
by chance, had a relative risk of 2.5, and all the homesteads with more than one patient 172 
were in this area. It was in a similar region to the high-risk cluster resulting from the local 173 
area-level analysis of the entire Hlabisa sub-district, in the south-east of the demographic 174 
surveillance area. This is the area around a township and is characterised by high population 175 
density and HIV prevalence compared to the rest of the demographic surveillance area.21 176 
There were no low relative risk clusters identified in this analysis.  177 
 178 
DISCUSSION 179 
In this study, we have described the spatial distribution of DRTB in the Hlabisa sub-district of 180 
KwaZulu-Natal for the first time. DRTB was highly prevalent in this region, with 489 (2.5%) of 181 
inpatients at Hlabisa hospital affected over a five-year period. Almost all had MDR disease 182 
and 16% died in hospital. There was clear evidence of a geographic high risk cluster of 183 
DRTB in the south-east of the region. This area is characterised by relatively high population 184 
density and high incidence and prevalence of HIV.21 This spatial heterogeneity of DRTB in a 185 
high burden, predominantly rural area was consistent with findings from lower HIV 186 
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prevalence settings, although our analysis was at a more granular level than most previous 187 
studies.6, 10, 11  188 
Establishing the spatial distribution of disease in rural areas such as the Hlabisa sub-district 189 
is challenging. This is because residential addresses are not recorded routinely in hospital 190 
systems, many people live in informal settlements which are not accurately mapped, and the 191 
population is highly mobile.24 A strength of our study is that we used precise residential 192 
locations collected in the AHRI demographic surveillance system. We were therefore able to 193 
derive the geographic distribution of DRTB from two different data sources: the self-reported 194 
local area of residence from hospital data, and, for residents of the AHRI demographic 195 
surveillance area, the homestead of residence. High risk clusters of disease were indicated 196 
in the same approximate area using both methods, suggesting that the observed clustering 197 
is genuine.  198 
The area of spatial clustering was characterised by high population density, and only 10 199 
(18%) patients in the cluster shared residences with other patients. This implies that 200 
transmission of DRTB in this community may have occurred in public places as well as 201 
within households. Other studies have also indicated the importance of community-based 202 
transmission of TB in similar settings.12, 25-30 Indoor venues with poor ventilation in which 203 
people come into close contact including healthcare facilities, public transport, churches and 204 
bars have been implicated as possible areas of transmission. An important component of 205 
DRTB prevention is therefore to identify such venues in the community and implement 206 
interventions including active case finding by regular screening; contact tracing; improving 207 
access to treatment, and airborne infection control measures in health facilities.  208 
The distinct spatial clustering of the disease suggests that targeting these interventions to 209 
suspected high transmission areas could be effective. However, our findings only reveal 210 
where people with DRTB reside, and uncovering precisely where transmission is occurring 211 
will require more detailed clinical and molecular epidemiology. A prospective cohort of 212 
people with DRTB is now operational in the study area where information is collected about 213 
social contact patterns and use of shared public spaces. This will be integrated with whole 214 
genome sequence data to provide better understanding of transmission. 215 
The results of our study also highlight the importance of the interaction between HIV and TB 216 
in this population. Almost three quarters of the patients with DRTB were HIV positive, 217 
compared to a prevalence in the population of approximately one quarter. The area of spatial 218 
clustering of DRTB was characterised by high HIV prevalence, and is in a similar region to a 219 
geographic cluster of HIV positive individuals identified previously.21 In this study population, 220 
approximately 60% of HIV positive patients were on antiretroviral therapy. Previous studies 221 
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have suggested that improved coverage of antiretroviral therapy at both the individual and 222 
community levels can contribute to reducing the incidence of TB.31-33 223 
Our study had several limitations. The analysis was restricted to DRTB patients, because we 224 
were only able to ascertain cases through hospital admissions data. Drug-sensitive TB 225 
patients are only admitted when clinically essential whereas policy at the time of the study 226 
was for all drug-resistant patients to be admitted for at least one month. We were therefore 227 
unable to determine whether the distribution of drug-resistant disease is similar to drug-228 
sensitive disease. Future studies in this area will integrate additional data from the electronic 229 
TB register (ETR.net) to characterise the distribution of drug-sensitive TB. 230 
The hospital information system used in this study also did not contain clinical information 231 
about history of treatment for TB. With the data available we therefore could not make any 232 
inference about the balance of primary and secondary drug resistance in the population. 233 
However, most recent data from high HIV prevalence settings suggest that, regardless of 234 
treatment history, the majority of DRTB cases arise from transmission.34  235 
Another limitation was the use of hospital discharge codes to define DRTB patients, which is 236 
an underestimate of the true number. We will have missed patients that were not coded in 237 
the hospital data as DRTB; children younger than 12 years who may have been managed 238 
elsewhere; individuals who had DRTB detected but did not go to hospital, and those with 239 
undetected disease. However, we have no reason to suspect that these factors would 240 
operate in a geographically heterogeneous way that would lead to spurious spatial clusters.  241 
The spatial analysis of DRTB in the wider Hlabisa sub-district was limited by use of local 242 
areas as opposed to individual addresses. However, results were similar to the analysis of 243 
precise point locations in the demographic surveillance area, which suggests that this 244 
method may be useful for similar analyses in future. We also used a hospital-based 245 
denominator as a proxy for the underlying population in this analysis. This will therefore be 246 
influenced by spatial factors which govern the distribution of conditions relating to other 247 
admissions. Finally, we described the characteristics of individuals using hospital data, but 248 
further information on patients would allow a more detailed analysis of risk factors in this 249 
population. 250 
CONCLUSIONS 251 
Our study shows concerning evidence of possible ongoing transmission of DRTB in this area 252 
of high prevalence. This suggests that targeting interventions to spatial areas of highest risk 253 
could be effective in supporting progress towards the WHO’s End TB strategy for a 90% 254 
reduction in new cases by 2035.35   255 
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TABLES 359 
Table 1: Characteristics of drug-resistant tuberculosis patients, Hlabisa hospital (2011-2015) 360 
Characteristic N % 
Sex 
 Male 
 Female 
 
239 
250 
 
48.9 
51.1 
Age group (years) 
 5-14 
 15-24 
 25-34 
 35-44 
 45-54 
 55-64 
 65-74 
 75+ 
 
10 
59 
166 
143 
66 
27 
10 
8 
 
2.0 
12.1 
33.9 
29.2 
13.5 
5.5 
2.0 
1.6 
Year of admission 
 2011 
 2012 
 2013 
 2014 
 2015 
 
77 
98 
103 
115 
96 
 
15.7 
20.0 
21.1 
23.5 
19.6 
Drug-resistant tuberculosis type 
 MDR 
 Rifampicin monoresistant 
 XDR 
 
478 
5 
6 
 
97.8 
1.0 
1.2 
Site of disease 
 Pulmonary 
 Extrapulmonary 
 Missing 
 
421 
5 
63 
 
86.1 
1.0 
12.9 
HIV/ ART status* 
 HIV positive, on ART 
 HIV positive, not on ART 
 HIV positive, ART missing 
 HIV negative 
 Missing 
 
202 
133 
5 
67 
82 
 
41.3 
27.2 
1.0 
13.7 
16.8 
13 
 
Discharge status 
 Discharged 
 Transferred 
 Died 
 Absconded 
 
394 
12 
78 
5 
 
80.6 
2.5 
16.0 
1.0 
MDR, multidrug-resistant; XDR, extensively drug-resistant; HIV, human immunodeficiency 361 
virus; ART, antiretroviral therapy. 362 
*at time of hospital admission 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
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FIGURES 383 
Figure 1: Study site 384 
A: Location of Hlabisa sub-district within South Africa 385 
B: Hlabisa sub-district, showing local areas and Africa Health Research Institute 386 
demographic surveillance area (shaded)  387 
C: Africa Health Research Institute demographic surveillance area, with roads and 388 
approximate locations of homesteads (incorporating intentional random error)389 
 390 
 391 
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Figure 2: Spatial clustering of drug-resistant tuberculosis in Hlabisa sub-district, 2011-2015. 392 
Locations determined using patient-reported local areas in hospital information system. 393 
 394 
 395 
 396 
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Figure 3: Spatial clustering of drug-resistant tuberculosis in Africa Health Research Institute 397 
demographic surveillance area, 2011-2015. Locations determined by linking hospital data to 398 
individual homesteads in demographic surveillance system. 399 
400 
 401 
